Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial
Top Cited Papers
- 1 July 2009
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 374 (9683) , 56-64
- https://doi.org/10.1016/s0140-6736(09)61117-x
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort studyBMJ, 2008
- Eliminating Human African Trypanosomiasis: Where Do We Stand and What Comes Next?PLoS Medicine, 2008
- Nifurtimox-Eflornithine Combination Therapy for Second-Stage Trypanosoma brucei gambiense Sleeping Sickness: A Randomized Clinical Trial in CongoClinical Infectious Diseases, 2007
- Nifurtimox plus Eflornithine for Late-Stage Sleeping Sickness in Uganda: A Case SeriesPLoS Neglected Tropical Diseases, 2007
- Three Drug Combinations for Late-Stage Trypanosoma brucei gambiense Sleeping Sickness: A Randomized Clinical Trial in UgandaPLoS Clinical Trials, 2006
- Effectiveness of a 10‐Day Melarsoprol Schedule for the Treatment of Late‐Stage Human African Trypanosomiasis: Confirmation from a Multinational Study (ImpamelII)The Journal of Infectious Diseases, 2005
- Prospects for Improving African Trypanosomiasis ChemotherapyThe Journal of Infectious Diseases, 2005
- The use of the acridine orange QBC® technique in the diagnosis of African trypanosomiasisTransactions of the Royal Society of Tropical Medicine and Hygiene, 1992
- High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central ZaireTransactions of the Royal Society of Tropical Medicine and Hygiene, 1992
- In vivo effects of α-dl-Difluoromethylornithine on the metabolism and morphology of Trypanosoma brucei bruceiMolecular and Biochemical Parasitology, 1983